Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRajapakse, S.-
dc.contributor.authorRajapakse, A.-
dc.identifier.citationJ Crit Care. 2009 Dec;24(4):609-13. Epub 2009 Feb 12en_US
dc.description.abstractSevere sepsis has a high mortality, and both incidence and mortality increases with increasing age. In recent years, several specific therapies have been recommended by guidelines to reduce mortality in severe sepsis. We review the age distribution in the key clinical trials on which these recommendations are made. Many therapeutic strategies have been evaluated, mainly in younger patients, with extrapolation of evidence toward the older population. Specific evidence of benefit in the elderly is present regarding treatment with activated protein C and ventilatory strategies. In view of the pharmacokinetic and pharmacodynamic differences in older people, and the higher incidence of comorbidity in the elderly, there is a need for clinical trials in severe sepsis to specifically include older patients.en_US
dc.titleAge bias in clinical trials in sepsis: how relevant are guidelines to older people?en_US
dc.typeJournal abstracten_US
Appears in Collections:Department of Clinical Medicine

Files in This Item:
File Description SizeFormat 
abs.txt859 BTextView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.